Acute-on-chronic inflammation in acute myocardial infarction
Open Access
- 21 August 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 39 (6) , 535-542
Abstract
Purpose of review: Acute myocardial infarction (AMI) is heralded by chronic inflammation and entails an excessive burst of acute-on-chronic inflammation (AoCI). This review describes the evolution from understanding atherosclerosis as a chronic inflammatory disease, to recent efforts in optimizing anti-inflammatory therapy to patients with AMI. It highlights the challenges and opportunities in selecting the optimal patient with AMI to derive maximal benefit from early anti-inflammatory therapy. Recent findings: The causal role of inflammation in atherosclerosis has been proven in large outcome trials. Since then, several smaller trials have sought to translate the concept of anti-inflammatory therapy targeting residual inflammatory risk to the dynamic early phase of AoCI after AMI. Current evidence highlights the importance of selecting patients with a high inflammatory burden. Surrogate criteria for large AMI (e.g., angiographic or electrocardiographic), as well as novel point-of-care biomarker testing may aid in selecting patients with particularly elevated AoCI. Additionally, patients presenting with AMI complicated by pro-inflammatory sequelae (e.g., atrial fibrillation, acute heart failure, left ventricular thrombosis) may dually profit from anti-inflammatory therapy. Summary: Improved understanding of the mechanisms and dynamics of acute and chronic inflammatory processes after AMI may aid the strive to optimize early anti-inflammatory therapy to patients with AMI.Keywords
This publication has 62 references indexed in Scilit:
- Increased Interleukin-6 is Associated with Higher Risk of Heart Failure in People with Type 2 DiabetesESC Heart Failure, 2024
- Quantifying Inflammation Using Interleukin-6 for Improved Phenotyping and Risk Stratification in Acute Heart FailureEuropean Journal of Heart Failure, 2023
- Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state modelAmerican Heart Journal, 2022
- Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillationAmerican Heart Journal, 2015
- Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: The Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trialAmerican Heart Journal, 2013
- Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]The American Journal of Cardiology, 2013
- Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)The American Journal of Cardiology, 2010
- Influence of ST-Segment Recovery on Infarct Size and Ejection Fraction in Patients With ST-Segment Elevation Myocardial Infarction Receiving Primary Percutaneous Coronary InterventionThe American Journal of Cardiology, 2010
- Association of Leukocyte and Neutrophil Counts With Infarct Size, Left Ventricular Function and Outcomes After Percutaneous Coronary Intervention for ST-Elevation Myocardial InfarctionThe American Journal of Cardiology, 2009
- Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillationThe American Journal of Cardiology, 2005